These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
416 related articles for article (PubMed ID: 34835108)
1. An Overview of Recent Insights into the Response of TLR to SARS-CoV-2 Infection and the Potential of TLR Agonists as SARS-CoV-2 Vaccine Adjuvants. Kayesh MEH; Kohara M; Tsukiyama-Kohara K Viruses; 2021 Nov; 13(11):. PubMed ID: 34835108 [TBL] [Abstract][Full Text] [Related]
2. Toll-Like Receptor 3 Signaling via TRIF Contributes to a Protective Innate Immune Response to Severe Acute Respiratory Syndrome Coronavirus Infection. Totura AL; Whitmore A; Agnihothram S; Schäfer A; Katze MG; Heise MT; Baric RS mBio; 2015 May; 6(3):e00638-15. PubMed ID: 26015500 [TBL] [Abstract][Full Text] [Related]
3. Toll-Like Receptor Signaling in Severe Acute Respiratory Syndrome Coronavirus 2-Induced Innate Immune Responses and the Potential Application Value of Toll-Like Receptor Immunomodulators in Patients With Coronavirus Disease 2019. Dai J; Wang Y; Wang H; Gao Z; Wang Y; Fang M; Shi S; Zhang P; Wang H; Su Y; Yang M Front Microbiol; 2022; 13():948770. PubMed ID: 35832809 [TBL] [Abstract][Full Text] [Related]
4. Current Understanding of the Innate Control of Toll-like Receptors in Response to SARS-CoV-2 Infection. Jung HE; Lee HK Viruses; 2021 Oct; 13(11):. PubMed ID: 34834939 [TBL] [Abstract][Full Text] [Related]
6. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity. Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P Cells; 2021 Oct; 10(11):. PubMed ID: 34831172 [TBL] [Abstract][Full Text] [Related]
7. Role of Toll-like receptors in the pathogenesis of COVID-19. Khanmohammadi S; Rezaei N J Med Virol; 2021 May; 93(5):2735-2739. PubMed ID: 33506952 [TBL] [Abstract][Full Text] [Related]
8. STING agonists as promising vaccine adjuvants to boost immunogenicity against SARS-related coronavirus derived infection: possible role of autophagy. Rezabakhsh A; Sadaie MR; Ala A; Roosta Y; Habtemariam S; Sahebnasagh A; Khezri MR Cell Commun Signal; 2024 Jun; 22(1):305. PubMed ID: 38831299 [TBL] [Abstract][Full Text] [Related]
9. Role of toll-like receptors in the pathogenesis of COVID-19: Current and future perspectives. Yang MY; Zheng MH; Meng XT; Ma LW; Liang HY; Fan HY Scand J Immunol; 2023 Aug; 98(2):e13275. PubMed ID: 38441378 [TBL] [Abstract][Full Text] [Related]
10. Adjuvants for Coronavirus Vaccines. Liang Z; Zhu H; Wang X; Jing B; Li Z; Xia X; Sun H; Yang Y; Zhang W; Shi L; Zeng H; Sun B Front Immunol; 2020; 11():589833. PubMed ID: 33240278 [TBL] [Abstract][Full Text] [Related]
11. Innate Receptor Activation Patterns Involving TLR and NLR Synergisms in COVID-19, ALI/ARDS and Sepsis Cytokine Storms: A Review and Model Making Novel Predictions and Therapeutic Suggestions. Root-Bernstein R Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672738 [TBL] [Abstract][Full Text] [Related]
12. Recent Insights into the Molecular Mechanisms of the Toll-like Receptor Response to Influenza Virus Infection. Kayesh MEH; Kohara M; Tsukiyama-Kohara K Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38892096 [TBL] [Abstract][Full Text] [Related]
13. An Evaluation of Type 1 Interferon Related Genes in Male and Female-Matched, SARS-CoV-2 Infected Individuals Early in the COVID-19 Pandemic. Huecksteadt TP; Myers EJ; Aamodt SE; Trivedi S; Warren KJ Viruses; 2024 Mar; 16(3):. PubMed ID: 38543837 [TBL] [Abstract][Full Text] [Related]
14. Differential Effects of Toll-Like Receptor Signaling on the Activation of Immune Responses in the Upper Respiratory Tract. Xu M; Li N; Fan X; Zhou Y; Bi S; Shen A; Wang B Microbiol Spectr; 2022 Feb; 10(1):e0114421. PubMed ID: 35196817 [TBL] [Abstract][Full Text] [Related]
15. Targeting Myeloid Differentiation Primary Response Protein 88 (MyD88) and Galectin-3 to Develop Broad-Spectrum Host-Mediated Therapeutics against SARS-CoV-2. Saikh KU; Anam K; Sultana H; Ahmed R; Kumar S; Srinivasan S; Ahmed H Int J Mol Sci; 2024 Aug; 25(15):. PubMed ID: 39125989 [TBL] [Abstract][Full Text] [Related]
16. cGAS-STING pathway agonists are promising vaccine adjuvants. Tian X; Ai J; Tian X; Wei X Med Res Rev; 2024 Jul; 44(4):1768-1799. PubMed ID: 38323921 [TBL] [Abstract][Full Text] [Related]
17. The effect of Toll-like receptor agonists on the immunogenicity of MVA-SARS-2-S vaccine after intranasal administration in mice. Do KTH; Willenzon S; Ristenpart J; Janssen A; Volz A; Sutter G; Förster R; Bošnjak B Front Cell Infect Microbiol; 2023; 13():1259822. PubMed ID: 37854858 [TBL] [Abstract][Full Text] [Related]
18. Toll-Like Receptors (TLRs) as Therapeutic Targets for Treating SARS-CoV-2: An Immunobiological Perspective. Patra R; Das NC; Mukherjee S Adv Exp Med Biol; 2021; 1352():87-109. PubMed ID: 35132596 [TBL] [Abstract][Full Text] [Related]
19. Effects of toll-like receptor agonists and SARS-CoV-2 antigens on interferon (IFN) expression by peripheral blood CD3 Abdolmohammadi-Vahid S; Baradaran B; Sadeghi A; Bezemer GFG; Kiaee F; Adcock IM; Folkerts G; Garssen J; Mortaz E Exp Mol Pathol; 2024 Jun; 137():104897. PubMed ID: 38691979 [TBL] [Abstract][Full Text] [Related]
20. Distinct single-component adjuvants steer human DC-mediated T-cell polarization via Toll-like receptor signaling toward a potent antiviral immune response. Roßmann L; Bagola K; Stephen T; Gerards AL; Walber B; Ullrich A; Schülke S; Kamp C; Spreitzer I; Hasan M; David-Watine B; Shorte SL; Bastian M; van Zandbergen G Proc Natl Acad Sci U S A; 2021 Sep; 118(39):. PubMed ID: 34561306 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]